Ophthalmology Education and CME

Select a Specialty

Going markerless

Going Markerless: A Cataract Suite for Advanced Results

This activity is sponsored by ZEISS.

April 12, 2019

We profiled three distinguished refractive cataract surgeons on their experience with the ZEISS Cataract Suite, as well as the benefits realized for their patients….

go to activity»
J768
CME

Preserving the Ocular Surface: Practice Pearls—Part IV

This activity is supported by educational grants from Alcon Laboratories, Inc.; Allergan, Inc.; Bausch + Lomb; Kala Pharmaceuticals; and Shire.

Expiration Date: 4/3/2020
Credit Type(s): CME | Credit: 0.75

Ocular surface disease (OSD) is a group of disorders commonly encountered in ophthalmic practice, but is challenging to diagnose and is often undertreated. However…

go to activity»
J773_HEA002
CME

MIGS and Cataract Surgery

This activity is supported by educational grants from Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Expiration Date: 4/2/2020
Credit Type(s): CME | Credit: 0.25

This educational video will discuss the benefits and complications of minimally invasive glaucoma surgery….

go to activity»
Rapid Response From Retina World Congress – Transitioning Treatment in Diabetic Retinopathy
CME

Rapid Response From Retina World Congress – Transitioning Treatment in Diabetic Retinopathy

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Expiration Date: 3/30/2020
Credit Type(s): CME | Credit: 0.75

Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, offering delayed or arrested disease progression and the…

go to activity»
J535
CME

ROCK-solid Inhibition in Glaucoma Therapy

This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.

Expiration Date: 3/17/2020
Credit Type(s): CME | Credit: 0.75

The medical management of glaucoma is primarily focused on lessening intraocular pressure (IOP) by reducing aqueous humor formation or improving the drainage of aqueous…

go to activity»
Retina 2019: What’s New in Tie2?
CME

Retina 2019: What’s New in Tie2?

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 2/20/2020
Credit Type(s): CME | Credit: 0.75

The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapy into management algorithms for the treatment of patients with neovascular retinal…

go to activity»
J582
CME

Diabetic Retinopathy: Assessing the Armamentarium for Improved Detection and Treatment

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 4/11/2020
Credit Type(s): CME | Credit: 0.75

Anti-VEGF therapy is an important addition to the treatment options for diabetic retinopathy (DR) and is the only medical option that has been granted US Food and Drug…

go to activity»
Cataract Surgery Alone Lowers Intraocular Pressure
CME

Cataract Surgery Alone Lowers Intraocular Pressure

This activity is supported by educational grants from Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Expiration Date: 4/2/2020
Credit Type(s): CME | Credit: 0.25

This educational activity will discuss the relationship between cataract surgery and IOP reduction….

go to activity»
Neuroprotection in Glaucoma
CME

Neuroprotection in Glaucoma

This activity is supported by educational grants from Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Expiration Date: 4/2/2020
Credit Type(s): CME | Credit: 0.25

This educational activity will review the latest developments and concepts regarding neuroprotection in patients with glaucoma….

go to activity»
1,800 Seconds™ in Advances in the Management of Age-Related Macular Degeneration
CME

1,800 Seconds™ in Advances in the Management of Age-Related Macular Degeneration

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation

Expiration Date: 3/31/2020
Credit Type(s): CME | Credit: 0.5

Age-related macular degeneration (AMD) is the leading cause of blind registration in industrialized countries, and the third leading cause of blindness internationally…

go to activity»
A Clearer Focus: Moving Forward to Improve the Management of Ocular Surface Disease.
CME

A Clearer Focus: Moving Forward to Improve the Management of Ocular Surface Disease

This activity is supported by an educational grant from Shire.

Expiration Date: 2/27/2020
Credit Type(s): CME | Credit: 0.75

Ocular surface disease (OSD) encompasses several disorders which include dry eye disease, blepharitis, meibomian gland dysfunction, ocular allergy, and conjunctivitis…

go to activity»
J843
CME

Long-term Management of Neovascular AMD: Meeting the Need for Improvement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Expiration Date: 2/13/2020
Credit Type(s): CME | Credit: 0.75

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment. As prevalence of AMD continues to increase, it is estimated…

go to activity»